Moderna's mRNA vaccine cuts melanoma recurrence risk by 42%

An mRNA vaccine developed by Moderna reduces the risk of melanoma recurrence or death from it by 42%. CEO Stephane Bancel said the results open a new chapter in cancer treatment. mRNA technology, known from COVID-19 vaccines, is now being tested as a weapon against skin cancer.